Raise led by Seven Seven Six and Aurelia Foundry in Partnership with Seraphim Space Expands LambdaVision’s Global Footprint

LambdaVision, a biotech innovator leveraging microgravity to manufacture its investigational protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, has closed a $7M seed funding round co-led by Seven Seven Six and Aurelia Foundry Fund, with additional support from Seraphim Space, providing runway into 2027. Millions of people worldwide lose their sight each year to retinal degenerative diseases like retinitis pigmentosa (RP) and age-related macular degeneration (AMD), with few effective treatment options. The funding will advance preclinical development and scale up space-enabled manufacturing of its artificial retina.

“Support from Seven Seven Six, Aurelia Foundry Fund, Seraphim Space, and other investors in the round underscores the growing recognition of the potential for space-based biomanufacturing to accelerate the development of life-changing therapies on Earth,” said Nicole Wagner, Ph.D., CEO of LambdaVision. “This seed round funding will help bring us closer to clinical trials and continue to pioneer scalable production of our artificial retina, including manufacturing techniques implemented in low-Earth orbit.”

By leveraging microgravity environments aboard the International Space Station (ISS), LambdaVision produces highly uniform, 200-layer protein thin films, a manufacturing capability challenging to replicate on Earth. This breakthrough accelerates the development of LambdaVision’s artificial retina for millions affected by RP and AMD. Nine successful ISS missions, in partnership with NASA and implementation partner Space Tango, have validated the process and refined LambdaVision’s space-based manufacturing methods, paving the way for scalable production and future clinical trials.

“LambdaVision is redefining what’s possible at the intersection of space and human health," said Katelin Holloway, Founding Partner at Seven Seven Six. "Their mission to restore vision through space-based biotechnology is deeply meaningful to me and a powerful example of how innovation beyond our planet can transform lives here on Earth. At Seven Seven Six, we’re proud to back founders who turn scientific breakthroughs into lasting human impact—and LambdaVision is doing exactly that.”

LambdaVision will build on this momentum and continue to fundraise in preparation for the launch of its Series A round. The announcement coincides with Wagner’s upcoming appearance at the Payload Investors Summit, where she will join leading voices in space commercialization and biotechnology to discuss the intersection of biomanufacturing, orbital infrastructure, and human health.

“LambdaVision is a perfect example of how the microgravity environment can unlock groundbreaking advances in human health,” said Ariel Ekblaw, Ph.D., Founding Partner of Aurelia Foundry Fund. “Their pioneering work at the intersection of space manufacturing and biotechnology showcases how orbital platforms can directly enable new classes of therapeutics. We’re thrilled to support LambdaVision as they translate their success in orbit into clinical impact here on Earth.”

"LambdaVision demonstrates the potential for space-enabled biotech to deliver transformative therapies on Earth,” said Rob Desborough, Partner at Seraphim Space. “We’re excited to support their journey as they scale their microgravity manufacturing platform toward clinical impact.”

With more than $15 million in prior funding from NASA, the National Science Foundation, and the National Eye Institute, LambdaVision has built a strong foundation of non-dilutive support. The company is now poised to bring its microgravity-manufactured artificial retina to clinical trials, advancing a new frontier in restoring vision for millions of patients around the world.

About LambdaVision

LambdaVision is leveraging space to develop a protein-based artificial retina to restore meaningful vision for the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The patent-protected artificial retina technology developed by LambdaVision uses photoactive proteins to naturally mimic the light-absorbing properties of human photoreceptor cells and activate neuroreceptors still present in degenerated retinas of blind patients. LambdaVision’s artificial retina is one of the first technologies being evaluated on the International Space Station that has potential for clinical use, and the established microgravity manufacturing processes, quality control methods, and laboratory techniques provide a foundation for future clinical research in space. To learn more, visit lambdavision.com.

About Seven Seven Sixeast

Seven Seven Six is an early-stage venture capital firm with over $1.1B AUM, focused on the intersection of product and people. Powered by the operating system Cerebro, at its heart, 776 is a technology company that deploys capital. The firm was founded in 2020 by Reddit co-founder Alexis Ohanian. Seven Seven Six invests across sectors, with investments spanning the creator economy, space, climate tech, sports, fintech, web3, healthcare, collectibles, and AI. Portfolio companies include Stoke Space, Feastables, Riverside.fm and Angel City FC, among others. For more information, visit sevensevensix.com.

About Aurelia Foundry

Aurelia Foundry is a deep tech space fund, investing in companies utilizing space for the benefit of life on Earth. As part of the broader Aurelia ecosystem, the fund works closely with the Aurelia Institute, a non-profit space architecture R&D lab, education and outreach center, and policy hub dedicated to building humanity’s future in space. The fund invests in both spin outs of the Institute and external startups building foundational technologies that will empower humanity.

About Seraphim Space

Founded in 2016, Seraphim is the world’s leading investment group focused on the space sector’s $trillion investment opportunity. Seraphim have pioneered ‘SpaceTech’ as an investment category, having launched both the world’s first private and first public SpaceTech focused VC funds. Through its combined offering of accelerators, VC funds and a listed growth fund (Seraphim Space Investment Trust), Seraphim provides the fuel to help the sector’s most ambitious entrepreneurs skyrocket – from pre-incorporation right through to pre-IPO. With a combined portfolio of more the 140 companies in more than 30 different countries, Seraphim Space is the most prolific investor in SpaceTech globally and recognised as a leading defence investor. Post Seraphim’s initial investment, portfolio companies have raised more than US$7.2 billion. Five portfolio companies have attained unicorn status, and 5 companies have become publicly listed.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105445558/en/